Biliary Tract Cancer Treatment Market 2034: Clinical Trials, FDA, EMA, PDMA Approvals, Incidence, Medication, Revenue, Statistics, Therapies, and Companies by DelveInsight

(Albany, USA) DelveInsight's "Biliary Tract Cancer Market Insights, Epidemiology, and Market Forecast-2034" report delivers an in-depth understanding of Biliary Tract Cancer, historical and forecasted epidemiology as well as the Biliary Tract Cancer market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

The Biliary Tract Cancer market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Biliary Tract Cancer market size from 2020 to 2034, segmented by seven major markets. The Report also covers current Biliary Tract Cancer treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Biliary Tract Cancer market.

Request for a Free Sample Report @ https://www.delveinsight.com/report-store/biliary-tract-cancers-btcs-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Some facts of the Biliary Tract Cancer Market Report are:
• According to DelveInsight, Biliary Tract Cancer market size is expected to grow at a decent CAGR by 2034.
• Leading Biliary Tract Cancer companies working in the market are Basilea Pharmaceutica, Zymeworks, BeiGene, Incyte Corporation, Loxo Oncology, Bayer, Roche, Genentech, QED Therapeutics, Agios Pharmaceuticals, Servier Pharmaceuticals, Merck Sharp & Dohme, AstraZeneca, Taiho Oncology, Delcath Systems, Eisai, and TransThera Sciences (Nanjing), and others.
• Key Biliary Tract Cancer Therapies expected to launch in the market are PEMAZYRE (pemigatinib), IMFINZI (durvalumab), CTX-009, Zanidatamab, and others.
• In March 2025, AstraZeneca announced a Phase 3b, Open-label, Multi-center Study on Durvalumab in Combination With Gemcitabine-based Chemotherapy as 1L Treatment for the Chinese Patients With Unresectable Biliary Tract Cancers (BTC) (TopDouble)
• In March 2025, AstraZeneca announced a Phase 3b, Single Arm, Open-label, Multicentre Study of Durvalumab in Combination With Chemotherapy for the First Line Treatment for Patients With Advanced Biliary Tract Cancers (TOURMALINE)
• In March 2025, AstraZeneca announced a Phase 3 Study of Trastuzumab Deruxtecan (T-DXd) and Rilvegostomig Versus Standard-of-Care Gemcitabine, Cisplatin, and Durvalumab for First Line Locally Advanced or Metastatic HER2-expressing Biliary Tract Cancer
• In March 2025, AstraZeneca announced Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Global Study of Rilvegostomig in Combination With Chemotherapy as Adjuvant Treatment After Resection of Biliary Tract Cancer With Curative Intent (ARTEMIDE-Biliary01)
• In March 2025, Suzhou Suncadia Biopharmaceuticals Co., Ltd announced a study on Adebrelimab With or Without SHR-8068 in Combination With Cisplatin Plus Gemcitabine as First-line Treatment in Patients With Advanced Biliary Tract Cancer: A Randomized, Open-label, Multicenter, Phase II Study
• In November 2024, Jazz Pharmaceuticals (Nasdaq: JAZZ) and Zymeworks (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced, with Jazz Pharmaceuticals, that the U.S. Food and Drug Administration (FDA) has granted accelerated approval of Ziihera® (zanidatamab-hrii) 50mg/mL for injection for intravenous use for the treatment of adults with previously-treated, unresectable or metastatic HER2-positive (IHC 3+) biliary tract cancer (BTC), as detected by an FDA-approved test.1 Ziihera was approved under accelerated approval based on a 52% objective response rate (ORR) and a median duration of response (DOR) of 14.9 months as determined by independent central review (ICR). Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.1 The approval of Ziihera, which previously received Breakthrough Therapy Designation from the FDA for this indication, is an important advance and offers the first and only dual HER2-targeted bispecific antibody and chemotherapy-free treatment for patients living with BTC.
• On April 2024, Jazz Pharmaceuticals announced results of a Phase 2b, Open-label, Single-arm Study of ZW25 Monotherapy in Subjects with Advanced or Metastatic HER2-amplified Biliary Tract Cancers.
• On March 2024, Genome & Company announced results of a Phase II Study to Evaluate the Safety and the Efficacy of GEN-001 in Combination with Pembrolizumab for Patients with Advanced Refractory Biliary Tract Cancer.
• On March 2024, AstraZeneca announced results of a Phase IIIb, Single Arm, Open-label, Multi-center Study on Durvalumab in Combination With Gemcitabine-based Chemotherapy as First Line Treatment for Chinese Patients With Unresectable Biliary Tract Cancers.
• On April 25, 2023, Jazz and Zymeworks entered into a Stock and Asset Purchase Agreement to, among other things, transfer to Jazz certain assets, contracts, and employees associated with the development of zanidatamab.

Biliary Tract Cancer Overvie
Biliary tract cancer encompasses tumors that develop in the bile ducts, which are responsible for transporting bile from the liver to the small intestine. These cancers can occur anywhere along the bile duct system, including the intrahepatic (within the liver), periphilar (at the bile duct's junction with the liver), and distal (closer to the small intestine) regions. Biliary tract cancer is relatively rare but often diagnosed at advanced stages, leading to a poor biliary tract cancer prognosis. Biliary tract cancer risk factors include chronic inflammation of the bile ducts, such as in primary sclerosing cholangitis, infection with liver flukes, and certain genetic conditions. Biliary tract cancer symptoms may include jaundice, abdominal pain, weight loss, and fatigue. Diagnosis typically involves imaging tests, such as CT scans and MRIs, and confirmation through biopsy. Biliary tract cancer treatment options depend on the cancer's stage and location but may include surgery, chemotherapy, radiation therapy, and targeted therapy. Early detection and multidisciplinary management are crucial for improving outcomes in patients with biliary tract cancer.

Learn more about Biliary Tract Cancer treatment algorithms in different geographies, and patient journeys. Contact to receive a sample @ https://www.delveinsight.com/sample-request/biliary-tract-cancers-btcs-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Biliary Tract Cancer Market
The Biliary Tract Cancer market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted Biliary Tract Cancer market trends by analyzing the impact of current Biliary Tract Cancer therapies on the market and unmet needs, and drivers, barriers, and demand for better technology.
This segment gives a thorough detail of the Biliary Tract Cancer market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Biliary Tract Cancer market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, the Biliary Tract Cancer market in 7MM is expected to witness a major change in the study period 2020-2034.

Biliary Tract Cancer Epidemiology
The Biliary Tract Cancer epidemiology section provides insights into the historical and current Biliary Tract Cancer patient pool and forecasted trends for seven individual major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Biliary Tract Cancer market report also provides the diagnosed patient pool, trends, and assumptions.

Explore more about Biliary Tract Cancer Epidemiology @ https://www.delveinsight.com/sample-request/biliary-tract-cancers-btcs-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Biliary Tract Cancer Drugs Uptake
This section focuses on the uptake rate of the potential Biliary Tract Cancer drugs recently launched in the Biliary Tract Cancer market or expected to be launched in 2020-2034. The analysis covers the Biliary Tract Cancer market uptake by drugs, patient uptake by therapies, and sales of each drug.
Biliary Tract Cancer Drugs Uptake helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs and allows the comparison of the drugs based on Biliary Tract Cancer market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Biliary Tract Cancer Pipeline Development Activities
The Biliary Tract Cancer report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses Biliary Tract Cancer key players involved in developing targeted therapeutics.

Request for a sample report to understand more about the Biliary Tract Cancer pipeline development activities @ https://www.delveinsight.com/sample-request/biliary-tract-cancers-btcs-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Biliary Tract Cancer Therapeutics Assessment
Major key companies are working proactively in the Biliary Tract Cancer Therapeutics market to develop novel therapies which will drive the Biliary Tract Cancer treatment markets in the upcoming years are Basilea Pharmaceutica (SIX: BSLN), Zymeworks (NASDAQ: ZYME), BeiGene (NASDAQ: ONC), Incyte Corporation (NASDAQ: INCY), Loxo Oncology (Acquired by Eli Lilly, no longer listed), Bayer (FWB: BAYN), Roche (SIX: ROG), Genentech (Acquired by Roche, no longer listed), QED Therapeutics (Privately held), Agios Pharmaceuticals (NASDAQ: AGIO), Servier Pharmaceuticals (Privately held), Merck Sharp & Dohme (NYSE: MRK), AstraZeneca (LSE: AZN), Taiho Oncology (Subsidiary of Otsuka Holdings, TYO: 4578), Delcath Systems (NASDAQ: DCTH), Eisai (TYO: 4523), TransThera Sciences (Nanjing), and others.

Learn more about the emerging Biliary Tract Cancer therapies & key companies @ https://www.delveinsight.com/sample-request/biliary-tract-cancers-btcs-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Biliary Tract Cancer Report Key Insights
1. Biliary Tract Cancer Patient Population
2. Biliary Tract Cancer Market Size and Trends
3. Key Cross Competition in the Biliary Tract Cancer Market
4. Biliary Tract Cancer Market Dynamics (Key Drivers and Barriers)
5. Biliary Tract Cancer Market Opportunities
6. Biliary Tract Cancer Therapeutic Approaches
7. Biliary Tract Cancer Pipeline Analysis
8. Biliary Tract Cancer Current Treatment Practices/Algorithm
9. Impact of Emerging Therapies on the Biliary Tract Cancer Market

Table of Contents
1. Key Insights
2. Executive Summary
3. Biliary Tract Cancer Competitive Intelligence Analysis
4. Biliary Tract Cancer Market Overview at a Glance
5. Biliary Tract Cancer Disease Background and Overview
6. Biliary Tract Cancer Patient Journey
7. Biliary Tract Cancer Epidemiology and Patient Population
8. Biliary Tract Cancer Treatment Algorithm, Current Treatment, and Medical Practices
9. Biliary Tract Cancer Unmet Needs
10. Key Endpoints of Biliary Tract Cancer Treatment
11. Biliary Tract Cancer Marketed Products
12. Biliary Tract Cancer Emerging Therapies
13. Biliary Tract Cancer Seven Major Market Analysis
14. Attribute Analysis
15. Biliary Tract Cancer Market Outlook (7 major markets)
16. Biliary Tract Cancer Access and Reimbursement Overview
17. KOL Views on the Biliary Tract Cancer Market
18. Biliary Tract Cancer Market Drivers
19. Biliary Tract Cancer Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer

Trending Reports:
• Angina Pectoris Market: https://www.delveinsight.com/report-store/angina-angina-pectoris-market
• Anorectal Malformation Market: https://www.delveinsight.com/report-store/anorectal-malformation-market
• Anovulation Market: https://www.delveinsight.com/report-store/anovulation-market
• Anterior Cruciate Ligament Injuries Market: https://www.delveinsight.com/report-store/anterior-cruciate-ligament-injuries-epidemiology-forecast
• Antibody Mediated Rejection Market: https://www.delveinsight.com/report-store/antibody-mediated-rejection-market
• Antiphospholipid Syndrome Aps Market: https://www.delveinsight.com/report-store/antiphospholipid-syndrome-aps-market
• Arthroscopic Shavers Market: https://www.delveinsight.com/report-store/arthroscopic-shavers-market
• Arthroscopy Devices Market: https://www.delveinsight.com/report-store/arthroscopy-devices-market
• Artificial Kidney Market: https://www.delveinsight.com/report-store/artificial-kidney-market
• Aspergillosis Market: https://www.delveinsight.com/report-store/aspergillosis-market
• Atherectomy Devices Market: https://www.delveinsight.com/report-store/atherectomy-devices-market
• Atypical Teratoid Rhabdoid Tumors Market: https://www.delveinsight.com/report-store/atypical-teratoid-rhabdoid-tumors-market
• Hyperhidrosis Market: https://www.delveinsight.com/report-store/axillary-hyperhidrosis-ahh-market
• Bacterial Pyogenic Meningitis Market: https://www.delveinsight.com/report-store/bacterial-pyogenic-meningitis-market
• Becker Muscular Dystrophy Market: https://www.delveinsight.com/report-store/becker-muscular-dystrophy-market
• Bile Duct Neoplasm Market: https://www.delveinsight.com/report-store/bile-duct-cancer-market
• Bipolar Depression Market: https://www.delveinsight.com/report-store/bipolar-disorder-manic-depression-market
• Blood Glucose Monitoring Systems Market: https://www.delveinsight.com/report-store/blood-glucose-monitoring-systems-market
• Bradycardia Treatment Devices Market: https://www.delveinsight.com/report-store/bradycardia-treatment-devices-market
• Bronchopulmonary Dysplasia Market: https://www.delveinsight.com/report-store/bronchopulmonary-dysplasia-market
• Bunion Market: https://www.delveinsight.com/report-store/bunion-market
• Cancer Anorexia Market: https://www.delveinsight.com/report-store/cancer-anorexia-market
• Capnography Device Market: https://www.delveinsight.com/report-store/capnography-devices-market
• Cardiotoxicity Market: https://www.delveinsight.com/report-store/cardiotoxicity-market
• Carpal Tunnel Syndrome Market: https://www.delveinsight.com/report-store/carpal-tunnel-release-system-market
• Catheter-related Bloodstream Infections Market: https://www.delveinsight.com/report-store/catheter-related-bloodstream-infection-crbsi-market-size-analysis

Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679
https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

This release was published on openPR.